UNSPSC 51384803: Phenazopyridine

This classification denotes a nonnarcotic analgesic with the molecular formula C11H11N5, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier K2J09EMJ52, chemically known as 2,6-pyridinediamine, 3- (phenylazo)-, monohydrochloride but more generally known as phenazopyridine, which bears U.S. NIH Compound Identifier 4756. European Medicines Agency schedules Phenazopyridine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09754MIG. The term PHENAZOPYRIDINE is an International Non-Proprietary Name.

World Health Organization schedules phenazopyridine in its Anatomical Therapeutic Chemical (ATC) Classification and its WHO-DD or Drug Dictionary. PHENAZOPYRIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

UNSPSC 51384803 Phenazopyridine is a Commodity code that in recent state and local activity covers pharmaceutical procurement — primarily generic multi-source drugs and over-the-counter products distributed through authorized wholesaler networks to public health systems, as well as specialized medications like naloxone acquired by county health departments for community health initiatives. The code captures both routine pharmaceutical supply contracts serving multiple jurisdictions through cooperative purchasing and single-jurisdiction acquisitions of targeted health-intervention drugs. State departments of health and human services, county health authorities, and cooperative purchasing alliances issue solicitations under this code; the issuing bodies range from single counties to multistate cooperative vehicles serving dozens of participating state and local entities.

Recent activity spans Florida and Texas at the county and state level, with multistate cooperative procurement through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) extending the reach to Oregon and other participating jurisdictions. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, an exploratory phase informing future formal procurement strategy. MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) with contract effectiveness targeted for July 1, 2026, and evaluation weighted heavily on price competitiveness at seventy-five percent.